Qualigen Therapeutics Statistics
Total Valuation
QLGN has a market cap or net worth of $3.83 million. The enterprise value is $7.12 million.
Important Dates
The next estimated earnings date is Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
QLGN has 1.70 million shares outstanding. The number of shares has increased by 806.00% in one year.
| Current Share Class | 1.70M |
| Shares Outstanding | 1.70M |
| Shares Change (YoY) | +806.00% |
| Shares Change (QoQ) | +15.59% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 3.21% |
| Float | 1.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.71
| Current Ratio | 0.71 |
| Quick Ratio | 0.06 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.97 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -171.67% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 373.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.75M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, QLGN has paid $9,367 in taxes.
| Income Tax | 9,367 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.52% in the last 52 weeks. The beta is -0.15, so QLGN's price volatility has been lower than the market average.
| Beta (5Y) | -0.15 |
| 52-Week Price Change | -73.52% |
| 50-Day Moving Average | 2.28 |
| 200-Day Moving Average | 3.31 |
| Relative Strength Index (RSI) | 62.69 |
| Average Volume (20 Days) | 212,593 |
Short Selling Information
The latest short interest is 34,368, so 2.03% of the outstanding shares have been sold short.
| Short Interest | 34,368 |
| Short Previous Month | 36,506 |
| Short % of Shares Out | 2.03% |
| Short % of Float | 2.03% |
| Short Ratio (days to cover) | 0.55 |
Income Statement
| Revenue | n/a |
| Gross Profit | 1.04M |
| Operating Income | -6.18M |
| Pretax Income | -11.64M |
| Net Income | -7.01M |
| EBITDA | n/a |
| EBIT | -6.18M |
| Earnings Per Share (EPS) | -$6.50 |
Full Income StatementBalance Sheet
The company has $331,601 in cash and $3.62 million in debt, giving a net cash position of -$3.29 million or -$1.94 per share.
| Cash & Cash Equivalents | 331,601 |
| Total Debt | 3.62M |
| Net Cash | -3.29M |
| Net Cash Per Share | -$1.94 |
| Equity (Book Value) | -1.65M |
| Book Value Per Share | -2.72 |
| Working Capital | -1.65M |
Full Balance SheetCash Flow
| Operating Cash Flow | -6.76M |
| Capital Expenditures | n/a |
| Free Cash Flow | -6.76M |
| FCF Per Share | -$3.99 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
